A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.
The study is being conducted to evaluate the safety, tolerability， preliminary efficacy, pharmacokinetics, and immunogenicity of SHR-A1811 combined with capecitabine in treatment of unresectable or metastatic breast cancer with low HER2 expression.
Breast Cancer
DRUG: SHR-A1811 for injection ; capecitabine
DLT（Phase I (dose exploration phase) ） [ Time Frame: 21 days after the first administration of each subject ], 21 days after the first administration of each subject ]|Incidence of AEs（Phase I (dose exploration phase) ）, from Day1 to 40 days after last dose|Incidence of SAEs（Phase I (dose exploration phase) ）, from Day1 to 40 days after last dose|Objective response rate（Phase II (efficacy expansion phase)）, One year after the last subject was enrolled in the group
Duration of response(DoR ), One year after the last subject was enrolled in the group|Progression Free Survival(PFS), One year after the last subject was enrolled in the group|Objective response rate（Phase I (dose exploration phase)）, One year after the last subject was enrolled in the group|Incidence of AEs（Phase II (efficacy expansion phase)）, from Day1 to 40 days after last dose|Incidence of SAEs（Phase II (efficacy expansion phase)）, from Day1 to 40 days after last dose
The study is being conducted to evaluate the safety, tolerability， preliminary efficacy, pharmacokinetics, and immunogenicity of SHR-A1811 combined with capecitabine in treatment of unresectable or metastatic breast cancer with low HER2 expression.